This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Shelli Avenevoli, Ph.D., the deputy director for the National Institute of Mental Health (NIMH), joined Cheddar to discuss concerns about the devastating impact the pandemic has had on the nation's youth. While mental health issues have been a point of concern for the populace at large, Avenevoli talked about how vulnerable young people have been during the COVID-19 crisis. "It's important to keep in mind, for children and adolescents, that the pandemic is occurring during a time of very formative development when social connection is vital for health and optimal function," she said. Avenevoli also noted broad political and social upheavals that have contributed to the issue but also things that can be done to help minors with their mental wellbeing.
Cheddar Innovates gets a look at the satellite that's searching for the earliest light from the big bang, plus a former Nike executive breaks down what the new era of sportswear looks like.
A packed Thursday pod: Carlo and Baker cover the latest developments in the Ghislaine Maxwell, Jussie Smollett and Elizabeth Holmes trials. Plus, Dems are losing the Hispanic vote, Boris Johnson in trouble again, and is it possible that Adele has peaked?
Adam Mosseri, head of Instagram, faced withering questions on Capitol Hill about the reports the social media app was aware of the severe mental health impacts it was having on teenage girls. Karen Kornbluh, the director of digital innovation and democracy for the German Marshall Fund, joined Cheddar to discuss the rare show of bipartisan outrage on display at the Senate hearing. "The senators came really loaded for bear on both sides of the aisle," she said. Kornbluh explained how senators like Richard Blumenthal (D-Conn.) set up fake Instagram accounts with teen girl profiles in order to research the effects firsthand.
A mental health crisis among young people is looming, and a large part of it is online. Cheddar News speaks with digital policy expert Karen Kornbluh on the issue.
Back in 2010, several large companies pledged to work towards stopping deforestation by 2020. Companies like Nestle and Carrefour even went further to say that they would eliminate deforestation from their supply chains altogether. However, fast forward to 2020, many of these companies have failed to reach that goal. Associate Director of Forest at the CDP Nadia Bishai, joined Cheddar to discuss more.
A new study by Pfizer-BioNTech found that a third dose of their COVID-19 vaccine is effective against the emerging omicron variant. The pharmaceutical giants also look to manufacture a vaccine specific to the omicron variant by March 2022.
